The cost-effectiveness of personalized genetic medicine: the case of genetic testing in neonatal diabetes.

ABSTRACT:

Objective

Neonatal diabetes mellitus is a rare form of diabetes diagnosed in infancy. Nearly half of patients with permanent neonatal diabetes have mutations in the genes for the ATP-sensitive potassium channel (KCNJ11 and ABCC8) that allow switching from insulin to sulfonylurea therapy. Although treatment conversion has dramatic benefits, the cost-effectiveness of routine genetic testing is unknown.

Research design and methods

We conducted a societal cost-utility analysis comparing a policy of routine genetic testing to no testing among children with permanent neonatal diabetes. We used a simulation model of type 1 diabetic complications, with the outcome of interest being the incremental cost-effectiveness ratio (ICER, $/quality-adjusted life-year [QALY] gained) over 30 ye

SUBMITTER: Greeley SA 

PROVIDER: S-EPMC3041194 | biostudies-literature | 2011 Mar

REPOSITORIES: biostudies-literature